siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies? ; year:2021
Advanced healthcare materials ; (2021)
- Urheber
- DOI
-
10.1002/adhm.202001650
- URN
-
urn:nbn:de:101:1-2021020308204420331114
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mehta, Aditi
- Michler, Thomas
- Merkel, Olivia
Ähnliche Objekte (12)
Engineering siRNA therapeutics: challenges and strategies
Human antibody therapeutics for viral disease
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Quantum dot therapeutics: a new class of radical therapies
Viral and non-viral systems to deliver gene therapeutics to clinical targets
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Non-viral siRNA delivery into the mouse retina in vivo
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics
Toxicological evaluation of poly(ethyleneimine)-based non-viral vector systems for pulmonary siRNA application
Transplantation therapeutics
Arithmetical therapeutics
Engineering siRNA therapeutics: challenges and strategies
Human antibody therapeutics for viral disease
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Quantum dot therapeutics: a new class of radical therapies
Viral and non-viral systems to deliver gene therapeutics to clinical targets
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Non-viral siRNA delivery into the mouse retina in vivo
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics
Toxicological evaluation of poly(ethyleneimine)-based non-viral vector systems for pulmonary siRNA application
Transplantation therapeutics
Arithmetical therapeutics
Engineering siRNA therapeutics: challenges and strategies
Human antibody therapeutics for viral disease
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Quantum dot therapeutics: a new class of radical therapies
Viral and non-viral systems to deliver gene therapeutics to clinical targets
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Non-viral siRNA delivery into the mouse retina in vivo
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics
Toxicological evaluation of poly(ethyleneimine)-based non-viral vector systems for pulmonary siRNA application
Transplantation therapeutics